2026 Q2 -tulosraportti
26 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14 min sittenA study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
·1 t sittenNew day, new catastrophe from Novo https://www.dr.dk/nyheder/indland/anders-blev-delvist-blind-af-wegovy-og-fik-millioner-i-erstatning-men-han-kunne-have-faaet-det
kentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
·2 t sittenRed today because fat people can't figure out how to use the medicine.It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
·10 t sittenSee, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
13 t sittenHi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.9 t sittenThe cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
26 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 min sittenA study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
- ·1 t sittenNew day, new catastrophe from Novo https://www.dr.dk/nyheder/indland/anders-blev-delvist-blind-af-wegovy-og-fik-millioner-i-erstatning-men-han-kunne-have-faaet-detkentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
- ·2 t sittenRed today because fat people can't figure out how to use the medicine.It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
- ·10 t sittenSee, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
- 13 t sittenHi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.9 t sittenThe cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
26 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 min sittenA study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
- ·1 t sittenNew day, new catastrophe from Novo https://www.dr.dk/nyheder/indland/anders-blev-delvist-blind-af-wegovy-og-fik-millioner-i-erstatning-men-han-kunne-have-faaet-detkentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
- ·2 t sittenRed today because fat people can't figure out how to use the medicine.It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
- ·10 t sittenSee, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
- 13 t sittenHi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.9 t sittenThe cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt